Evidence map›Paper›PMID 33273034›Full record

Observational studyJournal of medical genetics2022

Sensitivity and specificity of loss of heterozygosity analysis for the classification of rare germline variants in

Jan Hauke, Philipp Harter, Corinna Ernst, Alexander Burges, Sandra Schmidt, Alexander Reuss, Julika Borde, Nikolaus De Gregorio, Dimo Dietrich, Ahmed El-Balat and 15 more

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of medical genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 13 institutions in 1 country.

Jan Hauke *Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.ORCID 0000-0001-8236-4075
Philipp Harter *Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Nordrhein-Westfalen, Germany.
Corinna ErnstCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.ORCID 0000-0001-7756-8815
Alexander BurgesDepartment of Gynecology, University Hospital Munich-Großhadern, Munich, Bayern, Germany.
Sandra SchmidtCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
Alexander ReussCoordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Hessen, Germany.
Julika BordeCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
Nikolaus De GregorioDepartment of Gynecology and Obstetrics, University of Ulm and University Hospital Ulm, Ulm, Baden-Württemberg, Germany.
Dimo DietrichDepartment of Otolaryngology, Head and Neck Surgery, University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany.
Ahmed El-BalatDepartment of Gynecology, University of Frankfurt, Frankfurt am Main, Hessen, Germany.
Mohamad KayaliCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
Heidrun GevenslebenInstitute of Pathology, University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany.
Felix HilpertDepartment of Gynecology, University of Kiel, Kiel, Schleswig-Holstein, Germany.
Janine AltmüllerCologne Center for Genomics, University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
André HeimbachInstitute of Human Genetics, University of Bonn and University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany.
Werner MeierDepartment of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany.
Birgid Schoemig-MarkiefkaInstitute of Pathology, University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
Holger ThieleCologne Center for Genomics, University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
Rainer KimmigDepartment of Gynecology, University Hospital Essen, Essen, Nordrhein-Westfalen, Germany.
Peter NürnbergCologne Center for Genomics, University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
Karin KastDepartment of Gynecology and Obstetrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Lisa RichtersCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
Jalid SehouliDepartment of Gynecology and Gynecological Oncology, Charité, Berlin, Berlin, Germany.
Rita K SchmutzlerCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany.
Eric HahnenCenter for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Nordrhein-Westfalen, Germany eric.hahnen@uk-koeln.de.ORCID 0000-0002-1152-8367
University Hospital Cologne · DEUniversity Hospital Bonn · DEBayer (Germany) · DECharité - Universitätsmedizin Berlin · DEChristian-Albrechts-Universität zu Kiel · DEDüsseldorf University Hospital · DEEssen University Hospital · DEGoethe University Frankfurt · DEKliniken Essen-Mitte · DEPhilipps University of Marburg · DEUniversität Ulm · DEUniversity of Bonn · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variant-specific loss of heterozygosity (LOH) analyses may be useful to classify

Indexed as

Ovarian NeoplasmsBRCA1 ProteinBRCA2 ProteinFemaleGenes, BRCA1Genetic Predisposition to DiseaseGerm CellsGerm-Line MutationHumansLoss of HeterozygosityBRCA1 ProteinBRCA1 protein, humanBRCA2 Proteingenetic predisposition to diseasegenetic researchgenetic testinggerm-line mutation

Identifiers

PMID33273034
PMCPMC8867275
OpenAlexW3107501674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.